Supernus Price to Book Value from 2010 to 2024

SUPN Stock  USD 33.79  0.05  0.15%   
Check Supernus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Supernus main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.1 M, Interest Expense of 2.3 M or Total Revenue of 637.9 M, as well as many exotic indicators such as Short Term Coverage Ratios of 9.32, Price Earnings Ratio of 1.3 K or Price To Sales Ratio of 2.47. Supernus financial statements analysis is a perfect complement when working with Supernus Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Supernus Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Supernus Pharmaceuticals Technical models . Check out the analysis of Supernus Pharmaceuticals Correlation against competitors.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

About Supernus Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Supernus Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Supernus Pharmaceuticals investors use historical funamental indicators, such as Supernus Pharmaceuticals's Price to Book Value, to determine how well the company is positioned to perform in the future. Although Supernus Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Supernus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Supernus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Supernus Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Supernus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company was incorporated in 2005 and is headquartered in Rockville, Maryland. Supernus Pharm operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 603 people.

Currently Active Assets on Macroaxis

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:
Check out the analysis of Supernus Pharmaceuticals Correlation against competitors.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Supernus Stock analysis

When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
CEOs Directory
Screen CEOs from public companies around the world
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
0.02
Revenue Per Share
11.14
Quarterly Revenue Growth
(0.02)
Return On Assets
0.0056
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.